PropertyValue
?:abstract
  • The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and duration of efficacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine efficacy, duration of protection, safety, and mass vaccination.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.addr.2020.12.008
?:doi
?:journal
  • Adv_Drug_Deliv_Rev
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/74bad9ab3b88bea61af8a207dc349ca5505a9f41.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7744276.xml.json
?:pmcid
?:pmid
?:pmid
  • 33340620.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Non-viral COVID-19 vaccine delivery systems
?:type
?:year
  • 2020-12-17

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/3fyzk1wz>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/3fyzk1wz>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all